P3 Health Partners has seen its price target recalibrated, even as the core assumptions behind its fair value of $10.25 per share, the 12.5% discount rate, and roughly 6.1% revenue growth remain effectively intact. This tweak is being framed as a fine tuning of expectations around near term execution risk, not a reversal of confidence in the company’s long term earnings path. Read on to see how investors can stay ahead of these narrative shifts as new data points emerge.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value P3 Health Partners.

???? Bullish Takeaways

Lake Street continues to rate P3 Health Partners shares as Buy, signaling that, despite recent volatility, the firm still sees upside from current levels.

Analysts at Lake Street highlight that P3 is making progress operationally, even if that improvement is not yet fully visible in reported numbers. This supports the case for stronger earnings power over time.

The firm points to a much improved 2026 outlook as execution on current initiatives begins to show through. This underpins the revised $12.50 price target and supports the broader long term growth thesis.

???? Bearish Takeaways

Lake Street cut its price target to $12.50 from $20, reflecting tempered expectations around near term execution and profitability after what it called disappointing Q3 aEBITDA results.

The lower target underscores that some of the prior upside case has been marked down, with near term earnings risk and the timing of margin improvement now more prominent in the valuation debate.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

P3 Health Partners formed the P3 Commonwealth Innovation MSO with Commonwealth Primary Care ACO to expand value based care support for primary care physicians across five states and extend P3's footprint into Maricopa County, Arizona.

The new MSO will oversee shared services, financial management, compliance, data analytics, and clinical integration for participating ACOs. P3 will hold an 80% membership interest, majority board control, and potential future redemption rights over Commonwealth's stake.

On November 21, 2025, P3 received a Nasdaq notice for noncompliance with minimum stockholders' equity requirements. This starts a 45 day window to submit a remediation plan and potentially provides up to 180 days to regain compliance if the plan is accepted.

P3 reiterated management's confidence in its long term value creation and path to profitability. The company also revised 2025 revenue guidance to a range of $1,400 million to $1,450 million to reflect updated top line expectations.

Fair Value: Unchanged at $10.25 per share, indicating no revision to the intrinsic value estimate.

Discount Rate: Steady at 12.5%, reflecting an unchanged view of the company’s risk profile and required return.

Revenue Growth: Effectively unchanged at approximately 6.1%, with only an immaterial numerical refinement in the model.

Net Profit Margin: Fallen slightly from about 5.48% to 5.45%, indicating a marginally more conservative view on profitability.

Future P/E: Risen slightly from approximately 0.46x to 0.46x, suggesting a modestly higher valuation multiple applied to forward earnings.

Narratives on Simply Wall St turn P3 Health Partners' numbers into a clear story, connecting what the company does, how its revenue, earnings and margins might evolve, and what that implies for fair value. Each Narrative links the business outlook to a forecast and valuation, updates dynamically as news and earnings arrive, and helps investors compare fair value to the current share price, all within an easy to use Community experience trusted by millions.

Head over to the Simply Wall St Community and follow the Narrative on P3 Health Partners to stay up to date on:

How Medicare growth and value based care adoption could relate to recurring membership and long term revenue expansion.

Whether cost savings, payer renegotiations and technology investments translate into margin recovery by 2026.

How financing needs, Nasdaq compliance and execution risks might affect the gap between fair value and today’s price.

Read the full P3 Health Partners Narrative and track every update in real time.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PIII.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com